Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating. The firm views shares as 67% undervalued, the analyst tells investors in a research note. Should ivonescimab continue to deliver superior efficacy relative to a PD-(L)1 class, it could become one of the most successful drugs ever, the firm argues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Summit Therapeutics names Robert LaCaze as Chief Commercial Officer
- Sunrun, HubSpot, Rocket, Summit, Cybin: Trending by Analysts
- PepsiCo downgraded, HubSpot upgraded: Wall Street’s top analyst calls
- Summit Therapeutics initiated with an Outperform at Evercore ISI